Vemurafenib Delayed Progression in Metastatic, BRAF-Mutant CRC

Video
Conference|ASCO Gastrointestinal Cancer Symposium

This video covers results of the SWOG 1406 study, which tested the BRAF inhibitor vemurafenib in combination with irinotecan and cetuximab for patients with metastatic, BRAF-mutant colorectal cancer.

In this video, Scott Kopetz, MD, of the University of Texas MD Anderson Cancer Center in Houston, discusses results of the SWOG 1406 study, which tested the BRAF inhibitor vemurafenib in combination with irinotecan and cetuximab for patients with metastatic, BRAF-mutant colorectal cancer.

Dr. Kopetz presented results of the study (abstract 520) at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held January 19–21 in San Francisco.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Related Content
MEV01 trial results show that the test achieved an 86% early-stage sensitivity and 88% specificity in surveillance of HCC among patients with cirrhosis.

FDA Grants EvoLiver Biopsy Test Breakthrough Device Designation for HCC

Roman Fabbricatore
April 23rd 2025
Article

MEV01 trial results show that the test achieved an 86% early-stage sensitivity and 88% specificity in surveillance of HCC among patients with cirrhosis.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

3 Things You Should Know About Advances in Gastroesophageal Adenocarcinoma Therapy

3 Things You Should Know About Advances in Gastroesophageal Adenocarcinoma Therapy

ONCOLOGY Staff
April 17th 2025
Article

Immunotherapy combinations and targeted therapy options may help bridge clinical gaps in early-stage, locally advanced, and metastatic gastroesophageal adenocarcinomas.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Robot-Assisted Esophagectomy Achieves “Best Outcome Data” in Study

Robot-Assisted Esophagectomy Achieves “Best Outcome Data” in Study

Tim Cortese
April 14th 2025
Article

Robot-assisted minimally invasive esophagectomies with anastomotic technique were completed without complications or mortality in a majority of patients.

FDA OKs Nivolumab/Ipilimumab in Unresectable/Metastatic HCC

FDA OKs Nivolumab/Ipilimumab in Unresectable/Metastatic HCC

Ariana Pelosci;Tim Cortese
April 11th 2025
Article

Results from the phase 3 CheckMate 9DW trial of nivolumab/ipilimumab vs lenvatinib or sorafenib led to the approval for patients with unresectable or metastatic HCC.